Joseph Cappello - 16 Dec 2024 Form 4 Insider Report for GENELUX Corp (GNLX)

Reporting relationship: VP, Pharmaceutical Development
Issuer ticker: GNLX
Reported as of: 16 Dec 2024
Net transaction value: -$14,742
SEC form: 4
Accepted by SEC: 18 Dec 2024, 16:35:07 UTC
Prior SEC filing: 08 Jul 2024
Next SEC filing: 20 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Sean Ryder, Attorney-in-Fact

Key filing fact

Joseph Cappello filed Form 4 for GENELUX Corp (GNLX) on 18 Dec 2024.

Key facts

This page summarizes Joseph Cappello's Form 4 filing for GENELUX Corp (GNLX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Dec 2024, 16:35.

Change

Previous filing in this sequence was filed on 08 Jul 2024.
Current net transaction value: -$14,742.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GNLX transaction

Common Stock

Sale

Transaction value: $14,742
Shares: -6,300
Change %: -30%
Price: $2.34
Shares after: 14,653
Date: 16 Dec 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.